[Federal Register Volume 71, Number 124 (Wednesday, June 28, 2006)]
[Notices]
[Pages 36811-36812]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E6-10173]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Public Notice

AGENCY: Centers for Disease Control and Prevention (CDC), Health and 
Human Services (HHS).

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Centers for Disease Control and Prevention (CDC), 
Coordinating Center for Infectious Disease (CCID), through its 
component Centers and Divisions has lead technical responsibility for a 
number of Category A, B and C bioterrorism agents and their associated 
toxins (Bacillus anthracis, Clostridium botulinum, Brucella sps., 
Burkholderia sps., Staphylococcus entertoxin B, other food- or 
waterborne bacterial pathogens, and other bacterial agents). CCID uses 
epidemiologic, laboratory, clinical, and biostatistical sciences to 
control and prevent bacterial and mycotic infectious disease. The 
Centers also conduct applied research in a variety of settings, and 
translate the findings of this research into public health practice.
    The purpose of this announcement is to make interested parties 
aware that CCID is currently engaged in a research activity to 
establish and evaluate an intravenous infusion rabbit model for 
delivery of therapeutic molecules for the treatment of inhalation 
anthrax. The activity is in the early stage of feasibility assessment. 
The protocols for these studies may be made available to interested 
parties upon request. The short term objective of making these 
protocols available is to promote standardization of the approach to in 
vivo model development for anthrax therapy evaluation to meet the 
Nation's bioterrorism defense needs. The longer term objective is to 
develop these or subsequent protocols into standardized in vivo models 
that may meet the Food and Drug Administration (FDA) acceptance 
criteria for product development and licensure.
    Interested organizations may request an electronic copy of the 
protocols by contacting CDC at the address below. To ensure a response, 
requests must be submitted within thirty days of publication of this 
notice.
    Responses are preferred in electronic format and can be e-mailed to 
the attention of Dr. Conrad Quinn at [email protected]. Mailed responses 
can be sent to the following address: Dr. Conrad Quinn, Division of 
Bacterial Diseases, Coordinating Center for Infectious Diseases, 
Centers for Disease Control and Prevention, 1600 Clifton Rd., NE., Mail 
Stop C-09, Atlanta, GA 30333.

FOR FURTHER INFORMATION CONTACT:
    Technical: Dr. Conrad Quinn, Division of Bacterial and Mycotic 
Diseases, National Center for Infectious Diseases, Centers for Disease 
Control and Prevention (CDC), 1600 Clifton Rd., NE., Mail Stop D-11, 
Atlanta, GA 30333. Telephone (404) 639-2858, e-mail at [email protected].

[[Page 36812]]

    Business: Dr. Conrad Quinn, Division of Bacterial and Mycotic 
Diseases, National Center for Infectious Diseases, Centers for Disease 
Control and Prevention (CDC), 1600 Clifton R., NE., Mail Stop E-51, 
Atlanta, GA 30333. Telephone (404) 639-2858, e-mail at [email protected].

    Dated: June 20, 2006.
James D. Seligman,
Chief Information Officer, Centers for Disease Control and Prevention.
[FR Doc. E6-10173 Filed 6-27-06; 8:45 am]
BILLING CODE 4163-18-P